antipersonhood / Shutterstock.com
CV NEWS FEED // More than 100 organizations signed a letter to the Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services (HHS), asking the two organizations to protect American women and babies from mifepristone.
The May 14 letter, led by Americans United for Life (AUL) and the Ethics and Public Policy Center (EPPC), thanks Robert F. Kennedy, Secretary of the HHS, and Martin A Makary, FDA commissioner, for their work to improve American health.
“In the face of a dangerous drug, American women deserve the same resolve,” the letter states.
According to the letter, data from 2017 to 2023 indicates that from a sample of 865,727 prescribed chemical abortions, 94,605 women experienced serious adverse effects.
This data “indicates that more than one out of ten women are put at risk by mifepristone,” the letter states. “This real-world rate is twenty-two times greater than the rate claimed by the FDA.”
The letter added that nearly 11% of girls and women who take mifepristone experience sepsis, infection, hemorrhage, or another serious adverse event within 45 days. Despite this data, the Obama and Biden administrations both widened access to the dangerous drug.
The two administrations “not only removed the Risk Evaluation and Mitigation Strategy (REMS) requirements to report these serious consequences, it also removed protections like requiring a provider to meet with a woman in person before prescribing the drug to rule out dangerous conditions like ectopic pregnancies,” the letter continues.
“The FDA also removed requirements for the provider to follow up with a woman in person to check on her condition after she ingests mifepristone. It even removed the requirement that a doctor be involved at any stage in the chemical abortion process.”
The letter called on the FDA to start by reinstating the previous restrictions on mifepristone and to look more seriously at the dangers of the drug.
